other material
confidence high
sentiment neutral
materiality 0.50
Greenwich LifeSciences confirms FDA review of Phase IIb data, provides Flamingo-01 trial update
Greenwich LifeSciences, Inc.
- FDA reviewed Phase IIb clinical data before Flamingo-01 Phase III trial commencement.
- First US sites activated in Q3 2022; patient enrollment and treatment ongoing since Q4 2022.
- DTH skin tests and blood samples collected to assess immune response.
- Company planning expansion of Flamingo-01 clinical trial into Europe.
- Abstract and poster on Flamingo-01 design presented at AACR on April 17, 2023.